EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

HHV-6 and HHV-7 reactivation in allogeneic CAR-T cell therapy

Hiu Tung Chow, Wenjing Li, Bin Yang, Friedrich von Wintzingerode, Qi Chen

Trends in Biotechnology · 2025

DOI: 10.1016/j.tibtech.2025.03.017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2025. Verfasst von Hiu Tung Chow und 4 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, a Member of the Roche Group, 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: chow.cecilia@gene.com. Hauptthemen laut MEDLINE: Herpesvirus 6, Human, Immunotherapy, Adoptive, Virus Activation, Herpesvirus 7, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autologous chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment and allogeneic CAR-T cell therapy is poised to advance this revolution. CAR-T cell therapy faces some concerns regarding adventitious agents, which can threaten the safety of patients. Human herpesviruses 6 and 7 (HHV-6 and HHV-7) have become increasingly notable in this context, as they carry a risk with severe health consequences. This review explores these virus reactivations in CAR-T cell therapy and discusses mitigation strategies during allogeneic CAR-T cell manufacturing. We provide an overview of prevention and testing strategies, genetic engineering applications, and chemical substances with potential for interventions. This review aims to enhance understanding of HHV reactivation and improve the safety of allogeneic CAR-T cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 6, HumanImmunotherapy, AdoptiveVirus ActivationHerpesvirus 7, HumanReceptors, Chimeric AntigenRoseolovirus InfectionsHumans

Stichwörter der Autor:innen

CAR-THHV-6HHV-7cell therapy manufacturingvirus reactivationvirus safety

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Genentech, a Member of the Roche Group, 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: chow.cecilia@gene.com.
  • Genentech, a Member of the Roche Group, 1 DNA Way, South San Francisco, CA, 94080, USA.
  • Genentech, a Member of the Roche Group, 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: qi@gene.com.

Förderung

  • Roche
  • Genentech

Zitieren

APA

Chow, H. T., Li, W., Yang, B., von Wintzingerode, F., & Chen, Q. (2025). HHV-6 and HHV-7 reactivation in allogeneic CAR-T cell therapy. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2025.03.017

Vancouver

Chow HT, Li W, Yang B, von Wintzingerode F, Chen Q. HHV-6 and HHV-7 reactivation in allogeneic CAR-T cell therapy. Trends in Biotechnology. 2025. doi:10.1016/j.tibtech.2025.03.017

BibTeX
@article{Chow2025,
  author = {Chow, Hiu Tung and Li, Wenjing and Yang, Bin and von Wintzingerode, Friedrich and Chen, Qi},
  title = {HHV-6 and HHV-7 reactivation in allogeneic CAR-T cell therapy},
  journal = {Trends in Biotechnology},
  year = {2025},
  doi = {10.1016/j.tibtech.2025.03.017}
}
Kostenlos starten →